GLP-1

News

Large study points to benefits - and risks - of GLP-1 drugs

The largest observational study of GLP-1 weight-loss drugs suggests their benefits could be wide-ranging, but there are some risks to consider.

R&D

Life Sciences Industry Report 2025 pt2 cover

Life Sciences Industry Report 2025 - GLP-1S: Applicability i...

The pharmaceutical landscape in 2024 was undeniably shaped by the remarkable rise of GLP-1 receptor agonists.

News

Novo Nordisk asks FDA not to allow GLP-1 compounding

Novo Nordisk has asked the FDA to block compounders from making versions of its older, once-daily GLP-1 agonist liraglutide.

News

FDA approves flurry of drugs ahead of holiday season

The FDA has wrapped up a series of new approvals as 2024 draws to a close, with Novo Nordisk, Pfizer, Vertex, and Hikma among the beneficiaries.

News

Novo Nordisk sheds billions in value on obesity data

Novo Nordisk data on obesity candidate CagriSema falls short of expectations, wiping around $94 billion off its market valuation.

Patients

A new GLP-1 opportunity for pharma: Supporting patients’ emo...

People with obesity in Western cultures have largely been subject to shame, blame, stigma, and discrimination that condemns them for their current situation while simultaneously scorning th

Large study points to benefits - and risks - of GLP-1 drugs

Life Sciences Industry Report 2025 - GLP-1S: Applicability i...

Novo Nordisk asks FDA not to allow GLP-1 compounding

FDA approves flurry of drugs ahead of holiday season

Novo Nordisk sheds billions in value on obesity data

A new GLP-1 opportunity for pharma: Supporting patients’ emo...

Protego's $130m for amyloidosis drug, and other financings

How to meet your physicians where they are online

GLP-1

Editor's Picks